Acute Chest Syndrome: Clinical Trials

40 trials for Acute Chest Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 6 recruiting, 6 terminated, 4 unknown. 10 Not applicable, 10 Phase 2, 7 Phase 3, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable10Completed 4, Not yet recruiting 2, Terminated 2, Recruiting 1, Unknown 1
Phase 210Completed 6, Recruiting 2, Terminated 2
Phase 37Completed 2, Recruiting 2, Terminated 2, Withdrawn 1
Phase 14Completed 3, Withdrawn 1

Follow Acute Chest Syndrome: new trials by email Literature Review of Acute Chest Syndrome trials Research Report on Acute Chest Syndrome

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CPAP for Hypoxemic Acute Chest Syndrome in Sickle Cell Disease
O2+CPAP group - Sickle Cell Disease (SCD), Acute Chest Syndrome (ACS)
Not applicableNot yet recruitingAssistance Publique - Hôpitaux de Paris1402026-09-012026-07-23
Pleuropulmonary Ultrasound Imaging in Patients With Sickle Cell Disease in a Vaso-occlusive Crisis. "ECHODREP"
Pleuropulmonary ultrasound - Sickle Cell Disease (SCD), Vaso-Occlusive Crises
Not yet recruitingAssistance Publique - Hôpitaux de Paris2002026-09-012026-08-24
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
Lidocain, Placebo, Standard of care - Vaso-Occlusive Pain Episode in Sickle Cell Disease
Phase 3RecruitingNantes University Hospital1042026-07-032026-09-09
Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care
Injection of iohexol for glomerular filtration rate (GFR) measurement - Sickle Cell Disease, Glomerular Hyperfiltration
Not applicableRecruitingUniversity Hospital, Tours1002026-03-052026-03-10
Awake Prone Positioning for Severe Acute Chest Syndrome
Awake prone positioning (APP) - Acute Chest Syndrome, Sickle Cell Anemia
Not applicableNot yet recruitingAssistance Publique - Hôpitaux de Paris152026-01-012025-09-02
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%) - Sickle Cell Disease, Acute Chest Syndrome
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris1302025-08-272026-06-24
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
CSL889, Placebo - Sickle Cell Disease Vaso-occlusive Crisis
Phase 2RecruitingCSL Behring702025-07-102026-10-08
Ultrasound Acute Chest Syndrome Sickle Cell Disease
Point of Care Ultrasound - Acute Chest Syndrome, Sickle Cell Disease
Not applicableCompletedIndiana University272025-04-082026-09-02
Lung Ultrasound in Pediatric Acute Chest Syndrome
lung ultrasound - Sickle Cell Disease
UnknownAssistance Publique - Hôpitaux de Paris602024-06-302024-07-11
Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease
Red blood cell EXchange (REX) - Acute Chest Syndrome
Not applicableUnknownAssistance Publique - Hôpitaux de Paris1302024-03-012024-01-22
Use of Macrolides in Acute Chest Syndrome: A Multicenter Retrospective Study
Sickle Cell Disease, Acute Chest Syndrome
CompletedCentre Hospitalier de Saint-Denis2502023-06-012025-06-25
Tocilizumab for Acute Chest Syndrome
Tocilizumab - Sickle Cell Disease, Acute Chest Syndrome
Phase 2RecruitingUniversity of Chicago2002023-04-102026-09-15
Evaluation of Therapeutic Adherence to Inciting Spirometry in Sickle Cell Patients
Sickle Cell Disease
CompletedCentre Hospitalier Intercommunal Creteil152021-01-012021-02-23
Daily Vitamin D for Sickle-cell Respiratory Complications
Daily oral vitamin D3, 3,333 IU, Monthly oral vitamin D3, 100,000 IU, Placebo oral tablet - Sickle Cell Disease, Anemia, Sickle Cell
Phase 2CompletedColumbia University582020-09-152025-09-24
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
Brilinta, Placebo - Sickle Cell Disease
Phase 3WithdrawnAstraZeneca2020-06-302020-07-15
Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Hospitalized Sickle-cell Adults With Acute Chest Syndrome.
Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin, Control: usual antibiotic treatment - Acute Chest Syndrome, Sickle Cell Disease
Not applicableCompletedAssistance Publique - Hôpitaux de Paris722020-06-022025-03-24
Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin
Aspirin, Atorvastatin, Placebo Aspirin - Acute Chest Syndrome
Phase 3TerminatedDr. med. Mahir Karakas682020-02-212022-05-24
Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging
Sickle Cell Disease (SCD)
CompletedNational Heart, Lung, and Blood Institute (NHLBI)652018-02-272023-07-17
sPLA2 in EBC During Acute Chest Syndrome
Exhaled Breath Condensate (EBC), Plasma Sample - Sickle Cell Disease, Acute Chest Syndrome
CompletedVirginia Commonwealth University62018-01-192018-09-26
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
Defibrotide - Sickle Cell Disease, Acute Chest Syndrome
Phase 2CompletedNew York Medical College202018-01-122023-12-08

Showing 20 of 40. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (34)  ·  Vaso-Occlusive Crises (11)  ·  Asthma (3)  ·  Hypertension, Pulmonary (3)  ·  Respiratory Tract Infections (2)  ·  Vitamin D Deficiency (2)  ·  Acute Kidney Injury (1)  ·  Acute Lung Injury (1)  ·  Agnosia (1)  ·  Anemia (1)  ·  Anemia, Hemolytic (1)  ·  Anemia, Hemolytic, Congenital (1)  ·  Avitaminosis (1)  ·  Emergencies (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (40)  ·  Genetic Diseases, Inborn (40)  ·  Hematologic Diseases (40)  ·  Hemic and Lymphatic Diseases (40)  ·  Anemia (39)  ·  Anemia, Hemolytic (39)  ·  Anemia, Hemolytic, Congenital (39)  ·  Hemoglobinopathies (39)  ·  Lung Diseases (39)  ·  Respiration Disorders (39)  ·  Respiratory Tract Diseases (39)  ·  Anemia, Sickle Cell (6)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Bronchial Diseases (3)  ·  Cardiovascular Diseases (3)

Interventions

Cholecalciferol (2)  ·  Nitric Oxide (2)  ·  Standard of Care (2)  ·  tocilizumab (2)  ·  Administration, Oral (1)  ·  Albuterol (1)  ·  Aspirin (1)  ·  Atorvastatin (1)  ·  Azithromycin (1)  ·  Blood Transfusion (1)  ·  Dexamethasone (1)  ·  Endothelium-Dependent Relaxing Factors (1)  ·  Glomerular Filtration Rate (1)  ·  Hemopexin (1)  ·  Heparin (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (11)  ·  National Heart, Lung, and Blood Institute (NHLBI) (3)  ·  Albert Einstein College of Medicine (1)  ·  Alexhander Izhaki (1)  ·  Anthera Pharmaceuticals (1)  ·  AstraZeneca (1)  ·  CSL Behring (1)  ·  Carelon Research (1)  ·  Centre Hospitalier Intercommunal Creteil (1)  ·  Centre Hospitalier de Saint-Denis (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Columbia University (1)  ·  Craig Seaman (1)  ·  Dr. med. Mahir Karakas (1)  ·  Duke University (1)

Countries

United States (20)  ·  France (14)  ·  United Kingdom (2)  ·  Germany (1)  ·  Guadeloupe (1)  ·  Israel (1)  ·  Turkey (Türkiye) (1)

Top investigators

Alexander J Izhaki, MD (1)  ·  Alexandre Elabbadi, MD (1)  ·  Anders Berggren, MD, PhD (1)  ·  Armand Mekontso Dessap, MD, PhD (1)  ·  Arun S Shet, M.D. (1)  ·  Bernard Maitre, MD, PhD (1)  ·  Charles Quinn, MD (1)  ·  Claire Heilbronner, MD, PhD (1)  ·  Craig D Seaman, MD (1)  ·  Davis D Michael, PhD (1)  ·  Deepa Manwani, MD (1)

Results publications

PMID 24916507, PMID 26589907, PMID 19536844, PMID 20378559, PMID 21275961, PMID 21848879, PMID 22231150, PMID 22463614, PMID 22804353, PMID 23828202, PMID 26431718, PMID 29419434, PMID 29712666, PMID 33661274, PMID 37877609, PMID 39659429, PMID 39995490, PMID 40209087, PMID 41410575

NIH funding

U54HL070587 (2), 2023 (1), U10HL083721 (1)